Search results for "Heparin"

showing 10 items of 191 documents

Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular weight heparin.

2009

Introduction: We tested the efficacy and safety of fixed doses of Low-Molecular Weight Heparin (LMWH) in patients requiring interruption of Vitamin-k Antagonist (VKA) because of invasive procedures Methodology: Pre-operatively, patients discontinued VKA 5 +/- 1days; in those at low-risk for thrombosis, LMWH was given at a prophylactic dosage of 3.800 U.I. (nadroparin) or 4.000 U.I. (enoxaparin) anti-FXa once daily the night before the procedure. In patients at high-risk for thrombosis, LMWH was started early after VKA cessation and given at fixed sub-therapeutic doses (3.800 or 4.000 UI anti-FXa twice daily) until surgery. Post-operatively, LMWH was reinitiated 12 hours after procedure whil…

AdultMalemedicine.medical_specialtyBridging low molecular weight heparinTime FactorsVitamin Kmedicine.drug_classLow molecular weight heparinAdministration OralPostoperative HemorrhageRisk AssessmentDrug Administration ScheduleSettore MED/15 - Malattie Del SangueRisk FactorsThromboembolismmedicineHumansProspective StudiesEnoxaparinProspective cohort studyAgedAged 80 and overbusiness.industryIncidence (epidemiology)WarfarinAnticoagulantsNadroparinHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisConfidence intervalSurgeryLow Molecular Weight Heparin Fixed doses Chronic oral anticoagulation perioperative bridgingAnesthesiaSurgical Procedures OperativeNadroparinFeasibility StudiesFemaleWarfarinbusinessmedicine.drugFactor Xa Inhibitors
researchProduct

Home parenteral nutrition-associated thromboembolic and bleeding events: results of a cohort study of 236 individuals

2016

UNLABELLED Essentials Sparse or outdated studies focus on thrombotic and bleeding risk in home parenteral nutrition (HPN). 236 HPN patients followed at a single center for a total of 684 patient-years were evaluated. Rates of venous thrombosis and major bleeding, and prevalence of vena cava syndrome are provided. Anticoagulants might reduce thrombosis risk, but population-specific safety concerns remain. SUMMARY Background Home parenteral nutrition (HPN) is necessary for patients with intestinal failure. Recurrent catheter-related thrombosis (CRT) is common, leading to infectious complications, pulmonary embolism, vascular access loss and intestinal transplantation. The efficacy and safety …

AdultMalemedicine.medical_specialtyCatheterization Central VenousSuperior Vena Cava SyndromeHemorrhage030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineThromboembolismmedicineHumans030212 general & internal medicineProportional Hazards ModelsRetrospective Studiesbusiness.industryHeparinHazard ratioAnticoagulantsRetrospective cohort studyThrombosisHematologyVenous ThromboembolismMiddle Agedmedicine.diseaseThrombosisThrombocytopeniaPulmonary embolismSurgeryTransplantationVenous thrombosisParenteral nutritionTreatment OutcomeFemalebusinessParenteral Nutrition HomePulmonary EmbolismCohort study
researchProduct

Optimal duration of treatment in surgical patients with calf venous thrombosis involving one or more veins.

2006

The aim of this study was to evaluate different durations of treatment in patients with calf venous thrombosis (CVT) involving 1 or more deep veins. The authors studied 2 groups of patients with postsurgical CVT diagnosed by echo-color Doppler. The first group consisted of 68 patients with CVT involving a single vein, and the second group consisted of 124 patients with CVT involving 2 or more veins. Immediately after diagnosis, all patients were treated with nadroparin calcium and sodium warfarin. Heparin treatment was withdrawn after 5–6 days of treatment, when the international normalized ratio (INR) was stabilized between 2 and 3. Each group was divided into 2 subgroups receiving antico…

AdultMalemedicine.medical_specialtyFemoral vein030204 cardiovascular system & hematologyDrug Administration ScheduleLesion03 medical and health sciences0302 clinical medicinePostoperative ComplicationsMedicineHumans030212 general & internal medicineThrombusUltrasonography Doppler ColorVeinAgedVenous ThrombosisLegbusiness.industryAnticoagulantsNadroparinHeparinMiddle Agedmedicine.diseaseNadroparin calciumSurgeryVenous thrombosismedicine.anatomical_structureAnesthesiacardiovascular systemFemaleWarfarinmedicine.symptomCardiology and Cardiovascular MedicinebusinessSurgical patientsmedicine.drugAngiology
researchProduct

Heparin-induced priapism

2001

Heparin-induced priapism constitutes a special form of pharmaco-induced prolonged erection, but the pathophysiological principles are not yet definitely clear. Heparin-induced antiplatelet-antibodies may lead to the aggregation of thrombocytes and thus alter the penile blood flow leading to low-flow priapism. Alternatively, this condition may be explained by initial high-flow priapism that later turns into ischemic priapism. The question remains whether hemorrhage with subsequent organisation of the hematoma and late fibrosis constitutes a pathogenetic factor. Besides this pathogenetic discussion, this paper presents the differential diagnosis of priapism as well as diagnostic and therapeut…

AdultMalemedicine.medical_specialtyIschemic priapismHeparinbusiness.industryUrologyPriapismIschemiaHeparinurologic and male genital diseasesmedicine.diseaseSurgeryDiagnosis DifferentialHematomaInternal medicinemedicineCardiologyHumansPriapismDifferential diagnosisAgrégationbusinessmedicine.drugInternational Journal of Impotence Research
researchProduct

Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis

2014

Background— Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those findings. Methods and Results— In a randomized, double-blind, double-dummy trial of 2589 patients with acute VTE treated with low-molecular-weight or unfractionated heparin for 5 to 11 days, we compared dabigatran 150 mg twice daily with warfarin. The primary outcome, recurrent symptomatic, objectively confirmed VTE and related deaths during 6 months of treatment occurred in 30 of the 1279 dabigatran patients (2.3%) compared with 28 of the 1289 warfarin patients (2.2%; hazard ratio, 1.08; 95% confidence interval [CI], 0.…

AdultMalemedicine.medical_specialtyRE-COVER IIrecurrenceAntagonists & inhibitorsAdolescentvenous thromboembolismAntithrombinsDabigatranYoung AdultDouble-Blind MethodRisk FactorsPhysiology (medical)Internal medicinemedicineHumansdabigatrancardiovascular diseasesantagonists & inhibitorAgedacute venous thromboembolismHeparinbusiness.industryWarfarinFollow up studiesAnticoagulantsantagonists & inhibitors; hemorrhage; recurrence; thrombin; venous thromboembolism; warfarinHeparinHeparin Low-Molecular-WeightMiddle AgedthrombinSettore MED/11 - Malattie Dell'Apparato CardiovascolarewarfarinHeparin.low molecular weightPooled analysisAnesthesiaAcute Diseasebeta-AlanineBenzimidazolesFemaledabigatran; warfarin; acute venous thromboembolism; RE-COVER IIhemorrhageCardiology and Cardiovascular MedicinebusinessVenous thromboembolismFollow-Up Studiesmedicine.drug
researchProduct

Sulodexide versus calcium heparin in the medium-term treatment of deep vein thrombosis of the lower limbs.

1997

Thirty adult patients with distal, monolateral deep vein thrombosis of the lower limbs were randomly treated for sixty days either with subcutaneous Ca-Heparin or with Sulodexide, administered IM for ten days and orally for fifty days. The thrombus accretion above the knee, the venous pressures of the affected leg, the clinical sympto matology, and some laboratory coagulative tests were monitored throughout the admin istration period. Local tolerability of the two treatments was also evaluated.The two applied treatments evidenced a net antithrombotic activity, preventing thrombus accretion above the knee, improving with the same efficacy the venous pressures in the affected legs, and simila…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.drug_classDeep vein030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsHumansMedicine030212 general & internal medicineThrombusAgedGlycosaminoglycansmedicine.diagnostic_testHeparinbusiness.industryAnticoagulantHeparinMiddle AgedThrombophlebitismedicine.diseaseThrombosisSulodexideSurgerymedicine.anatomical_structureTolerabilityAnesthesiaSettore BIO/14 - FarmacologiaFemaleAdult Aged Female Fibrinolytic Agents/administration & dosage Fibrinolytic Agents/therapeutic use* Glycosaminoglycans/administration & dosage Glycosaminoglycans/therapeutic use* Heparin/therapeutic use* Humans Male Middle Aged Thrombophlebitis/drug therapy*Cardiology and Cardiovascular Medicinebusinessmedicine.drugPartial thromboplastin time
researchProduct

Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT).

2021

Objective Management and outcomes of superficial vein thrombosis (SVT) are highly variable and not well described. Therefore, the INvestigating SIGnificant Health TrendS in the management of SVT (INSIGHTS-SVT) study collected prospective data under real life conditions. Methods Prospective observational study of objectively confirmed acute isolated SVT. The primary outcome was a composite of symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), and extension or recurrence of SVT at three months. The primary safety outcome was clinically relevant bleeding. Results A total of 1 150 patients were included (mean age 60.2 ± 14.7 years; 64.9% women; mean BMI 29.4 ± 6.3 kg/m2). SVT was …

AdultMalemedicine.medical_specialtySuperficial vein thrombosismedicine.drug_classDeep veinLow molecular weight heparinHemorrhage030204 cardiovascular system & hematology030230 surgeryFondaparinuxVaricose Veins03 medical and health sciences0302 clinical medicineRecurrenceRisk FactorsmedicineHumansProspective StudiesAgedAged 80 and overVenous Thrombosisbusiness.industryHazard ratioLeg UlcerAnticoagulantsHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisPulmonary embolismSurgeryVenous thrombosismedicine.anatomical_structureTreatment OutcomeFondaparinuxLower ExtremityVenous InsufficiencySurgeryFemaleCardiology and Cardiovascular MedicinebusinessPulmonary EmbolismStockings Compressionmedicine.drugFactor Xa InhibitorsEuropean journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
researchProduct

Advantages of immediate two-dimensional echocardiography in patients with acute cardiac ischemic events

1995

Abstract We hypothesized that the assessment of kinetic alterations on two dimensional echocardiogram (2DE) would provide greater diagnostic information than clinical symptoms and ECG changes only. The study was aimed to determine sensitivity of 2DE in patients with cardiac ischemic events and to improve the indications to thrombolysis. Three-hundred ninety-one patients (87 F; 304 M) hospitalized for suspected acute myocardial infarction (AMI), first episode, within 4 h from the onset of symptoms, suitable for thrombolysis Killip class I–II and with unstable angina (UA), were admitted in the study. Patients had to show ECG changes and alterations of segmentary motion on 2DE performed at ent…

AdultMalemedicine.medical_specialtySystolemedicine.medical_treatmentMyocardial InfarctionMyocardial IschemiaIschemiaInfarctionSensitivity and SpecificityVentricular Function LeftElectrocardiographyFibrinolytic AgentsInternal medicinemedicineHumansThrombolytic TherapyAngina Unstablecardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryCoronary Artery BypassCreatine KinaseAgedKillip classAged 80 and overFirst episodeHeparinVascular diseaseUnstable anginabusiness.industryThrombolysisMiddle Agedmedicine.diseaseIsoenzymesSurvival RateEchocardiographyVentricular Function RightCardiologyFemaleCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

The effect of two low doses of aspirin on whole blood thromboxane and prostacyclin generation in healthy subjects

1983

SummaryThe effects of two low doses of aspirin (20 mg and 100 mg) on prostacyclin and thromboxane formation during whole blood clotting were studied in 8 healthy volunteers.A single 100 mg aspirin dose caused more than 90% reduction of both serum TXB2 and 6-keto-PGF1α; a single 20 mg dose of aspirin inhibited serum TXB2 more than 6-keto-PGF1α but effects on these two products could not be completely dissociated.However, the effect of a single 20 mg aspirin dose on serum TXB2, was of much longer duration than its inhibitory effect on PGI2 synthesis during whole blood clotting.

AdultMalemedicine.medical_specialtyTime Factorsmedicine.drug_classThromboxaneAlpha (ethology)Prostacyclin6-Ketoprostaglandin F1 alphaInternal medicinemedicineHumansCyclooxygenase InhibitorsBlood CoagulationWhole bloodAspirinAspirinChemistryAnticoagulantLow doseThromboxanesHematologyHeparinEpoprostenolThromboxane B2EndocrinologyFemalelipids (amino acids peptides and proteins)circulatory and respiratory physiologymedicine.drug
researchProduct

Dose-Adjusted Thrombosis Prophylaxis in Trauma Surgery According to Levels of D-Dimer

2000

In 234 trauma surgery patients, thrombosis prophylaxis with Nadroparin-Calcium low-molecular-weight heparin (LMWH) was adjusted according to levels of D-Dimer. Basic prophylaxis was 2,850 IU per day. If D-Dimer concentrations rose above 2 mg/L after the fourth postoperative (p.o.) day, LMWH was administered twice a day. Color Doppler ultrasound was performed between the fifth and seventh p.o. days. Patients were divided into a high-risk (group 1: hip, femur, or knee replacement surgery, n=102) and a moderate-risk group (group 2: other surgery of the knee, tibia, fibula, or foot, n=132). Group 1 showed significantly higher D-Dimer levels than group 2 (p0.001). Measurement of D-Dimer on days …

AdultMalemedicine.medical_specialtyTime Factorsmedicine.drug_classmedicine.medical_treatmentDeep veinAntithrombin IIIKnee replacementLow molecular weight heparinSensitivity and SpecificityFibrin Fibrinogen Degradation ProductsFractures BoneRisk FactorsAntifibrinolytic agentD-dimerHumansMedicineAgedAged 80 and overVenous Thrombosisbusiness.industryAnticoagulantNadroparinHematologyMiddle Agedmedicine.diseaseAntifibrinolytic AgentsSurgeryVenous thrombosismedicine.anatomical_structureAnesthesiaWounds and InjuriesFemalebusinessTrauma surgeryBiomarkersLeg InjuriesPeptide HydrolasesThrombosis Research
researchProduct